Acute Respiratory Distress Syndrome (ARDS) Market to Grow at a CAGR of 10.31% by 2032 – Asserts DelveInsight

Acute Respiratory Distress Syndrome (ARDS) Market to Grow at a CAGR of 10.31% by 2032 - Asserts DelveInsight
Delveinsight Business Research LLP
As per DelveInsight, the Acute Respiratory Distress Syndrome Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of ARDS in the 7MM.

Expected launch of emerging therapies, such as Traumakine (Faron Pharmaceuticals) BIO-11006 (BioMarck Pharmaceuticals), MultiStem (Athersys), Solnatide (Apeptico Forschung und Entwicklung GmbH), PB1046 (PhaseBio Pharmaceuticals), and others are anticipated to create a positive impact on the treatment scenario and market outlook in the coming years. 

DelveInsight’s “Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Respiratory Distress Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Acute Respiratory Distress Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Acute Respiratory Distress Syndrome: An Overview

Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease in critically ill patients. The major complication in ARDS is marked by fluid leakage into the lungs, making breathing difficult or impossible.

Acute lung injury (ALI) is a common condition characterized by acute severe hypoxia that is not due to left atrial hypertension. The term ALI encompasses a continuum of clinical and radiographic changes that affect the lungs, with acute respiratory distress syndrome (ARDS) representing the more severe end of this continuum. Despite advances in the understanding of the pathophysiology and management of ALI, it is still associated with high mortality.

The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.

Upcoming therapies such as MultiStem, Zyesami (Aviptadil), and others have the potential to create a significant positive shift in the Acute Respiratory Distress Syndrome market size.

Acute Respiratory Distress Syndrome Market Key Facts

  • The United States accounts for the largest market size for Acute Respiratory Distress Syndrome compared to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

  • Among the EU5 countries, Germany had the highest market size, with approximately USD 166.2 million, followed by France in 2021.

  • In 2021, the total incident cases of ARDS were estimated to be 1,088,000+ cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 1.5% during the study period (2019–2032).

  • Among the 7MM, the United States has the highest number of incident cases of ARDS, with approximately 630,000+ cases in 2021.

  • Generally, among the 7MM countries, the primary risk factor associated with the highest number of incident cases of ARDS was pneumonia, except for the United Kingdom, where sepsis was the primary risk factor for ARDS

  • Among the EU-5, Germany had the highest total incident population of ARDS with 193,828 cases, followed by France (73,541 cases) and Italy with 55,522 cases in 2021. On the other hand, Spain (31,286 cases) had the lowest incident population for 2021.

  • In 2021, Japan had approximately 69,628 total incident cases of ARDS, which are expected to increase by 2032 at a CAGR of 0.5% during the study period (2019–2032).

Acute Respiratory Distress Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Acute Respiratory Distress Syndrome market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Acute Respiratory Distress Syndrome market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Acute Respiratory Distress Syndrome Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Acute Respiratory Distress Syndrome Epidemiology, Segmented as –

  • Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM [2019–2032]

  • Incident Population of Acute Respiratory Distress Syndrome (ARDS) by risk factors in the 7MM [2019–2032]

  • Severity-specific Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM [2019–2032]

Acute Respiratory Distress Syndrome Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Acute Respiratory Distress Syndrome market or expected to be launched during the study period. The analysis covers the Acute Respiratory Distress Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Respiratory Distress Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Acute Respiratory Distress Syndrome Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

Acute Respiratory Distress Syndrome Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Acute Respiratory Distress Syndrome. Currently, Athersys is leading the therapeutics market with its Acute Respiratory Distress Syndrome drug candidates in the most advanced stage of clinical development.

The Leading Players in the Acute Respiratory Distress Syndrome Therapeutics Market Include:

Abbreos, Aerpio Pharmaceuticals, Apeiron Biologics, APEPTICO Forschung und Entwicklung GmbH, Arch Biopartners, Athersys, Avalo Therapeutics, Aviceda Therapeutics, AVM Biotechnology, Bayer, Biohaven Pharmaceutical, BioMarck Pharmaceuticals, Boehringer Ingelheim, Cartesian Therapeutics, CohBar, Cynata Therapeutics, Direct Biologics, Edesa Biotech, Exvastat, Faron Pharmaceuticals, GEn1E Lifesciences, Genentech, Healios, ILTOO Pharma, ImStem Biotechnology, Light Chain Biosciences, Longeveron, MediciNova, Mesoblast Limited, Orbsen Therapeutics, Pluristem Therapeutics, Roivant Sciences, Sage Therapeutics, Staidson (Beijing) Biopharmaceuticals, Veru, Windtree Therapeutics, ZyVersa Therapeutics, and others.

Acute Respiratory Distress Syndrome Emerging and Marketed Drugs Covered in the Report Include

  • Alteplase (Actilyse): Boehringer Ingelheim/ Genentech

  • BIO-11006: BioMarck Pharmaceuticals

  • EB05: Edesa Biotech

  • ExoFlo (DB-001): Direct Biologics

  • HCR040: Histocell, S.L.

  • HLCM051(MultiStem): Healios

  • MultiStem: Athersys

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Acute Respiratory Distress Syndrome Competitive Intelligence Analysis

4. Acute Respiratory Distress Syndrome Market Overview at a Glance

5. Acute Respiratory Distress Syndrome Disease Background and Overview

6. Acute Respiratory Distress Syndrome Patient Journey

7. Acute Respiratory Distress Syndrome Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Acute Respiratory Distress Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Respiratory Distress Syndrome Unmet Needs

10. Key Endpoints of Acute Respiratory Distress Syndrome Treatment

11. Acute Respiratory Distress Syndrome Marketed Products

12. Acute Respiratory Distress Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Acute Respiratory Distress Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Acute Respiratory Distress Syndrome Market Outlook (In US, EU5, and Japan)

16. Acute Respiratory Distress Syndrome Access and Reimbursement Overview

17. KOL Views on the Acute Respiratory Distress Syndrome Market

18. Acute Respiratory Distress Syndrome Market Drivers

19. Acute Respiratory Distress Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

 

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Strategies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: